NEO-201-reactive truncated O-glycan epitope

The NEO-201-reactive truncated O-glycan epitope is a tumor-associated carbohydrate antigen (TACA) primarily found on glycoproteins such as CEACAM5, CEACAM6, and MUC1 (Fantini et al., 2020) [1]. This epitope arises from aberrant O-glycosylation processes common in malignant transformation, leading to the exposure of truncated sugar chains that are typically masked in healthy tissues (Zeytin et al., 2018) [2]. A distinctive feature of this target is its expression on a specific subset of regulatory T cells (Tregs) found in the circulation of patients with various solid tumors, including colorectal, pancreatic, and lung cancers (David et al., 2021) [3]. The humanized monoclonal antibody NEO-201 specifically binds to this epitope, triggering immune-mediated destruction of both tumor cells and the associated Treg subset via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (Precision Biologics) [4]. By depleting these immunosuppressive Tregs, NEO-201 may help restore the host's anti-tumor immune response and improve the efficacy of concurrent treatments like checkpoint inhibitors (Fantini et al., 2022) [5]. Clinical studies are currently evaluating the safety and therapeutic potential of targeting this epitope in patients with advanced refractory cancers. [1] Fantini M, et al. (2020). Front Immunol. [2] Zeytin H, et al. (2018). J Clin Oncol. [3] David V, et al. (2021). Clin Cancer Res. [4] Precision Biologics. NEO-201 Overview. [5] Fantini M, et al. (2022). Cancer Immunol Immunother.

Other names

NEO-201 antigenTruncated O-glycan on CEACAM5/6Tumor-associated carbohydrate antigen (TACA)Regulatory T cells expressing NEO-201-reactive truncated O-glycan epitopes

Induction of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against tumor cells and a specific subset of regulatory T cells expressing the epitope.